The Effects of Rituximab on Lipids, Arterial Stiffness, and Carotid Intima-Media Thickness in Rheumatoid Arthritis

다국어 초록 (Multilingual Abstract)

The aim of the study was to examine lipid profiles, arterial stiffness (AS), and carotid intima-media thickness (cIMT), in 55 women with RA without overt cardiovascular disease (CVD) treated with rituximab (RTX).The following parameters were recorded before and 24 weeks after RTX therapy (2 infusions of 500 or 1,000 mg RTX intravenously, fortnightly): plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, DAS 28-ESR, serum C-reactive protein (CRP), RF IgM, AS (SI - stiffness index, RI – reflection index) by digital volume pulse contour analysis (Micro Medical, UK), and common cIMT by high-resolution B-mode carotid ultrasound. Based on the European League Against Rheumatism (EULAR) criteria, patients were divided into two groups: 1) moderate/good response to RTX therapy after 24 weeks (41 patients, 75%), 2) no response to RTX therapy (14 patients, 25%). Effective RTX therapy resulted in 9% increase in TC, 23% increase in HDL-C and 14% decrease in atherogenic index, 57% decrease in SI and 24% decrease in RI. We observed a 9% decrease of cIMTmax at 24 weeks. The improvement of cardiovascular parameters was accompanied by statistically significant decreases of CRP, ESR, RF IgM, and DAS 28 in group 1 (P < 0.05). There were no significant changes in lipid profile, AS parameters, and cIMT in group 2. Two infusions of RTX in case of moderate/good EULAR effect of therapy exerted favorable effects on lipid profile, AS and cIMT in women with RA without overt CVD.

참고문헌 (Reference)

1 Gasparyan AY, "The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases" 8 : 437-449, 2010

2 Provan SA, "The impact of newer biological disease modifying antirheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab" 10 : e0130709-, 2015

3 Novikova DS, "The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis" 18 : 1512-1518, 2012

4 "The Arthritis, Rheumatism, and Aging Medical Information System" HAQ

5 Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis" 31 : 315-324, 1988

6 Tsiantoulas D, "Targeting B cells in atherosclerosis: closing the gap from bench to bedside" 35 : 296-302, 2015

7 del Rincón I, "Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis" 74 : 1118-1123, 2015

8 Gonzalez-Juanatey C, "Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy" 59 : 1821-1824, 2008

9 Chatzidionysiou K, "Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort" 42 : 190-195, 2013

10 Aviña-Zubieta JA, "Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies" 59 : 1690-1697, 2008

11 Mellana WM, "Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy" 18 : 1450-1456, 2012

12 Emery P, "Rheumatoid arthritis in 2014: exciting times for RA research" 11 : 69-70, 2015

13 Ambrosino P, "Non-invasive assessment of arterial stiffness in patients with rheumatoid arthritis: a systematic review and meta-analysis of literature studies" 47 : 457-467, 2015

14 Mathieu S, "No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment" 51 : 1107-1111, 2012

15 van Sijl AM, "Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?" 20 : 496-499, 2014

16 Touboul PJ, "Mannheim intima-media thickness consensus" 18 : 346-349, 2004

17 van Vollenhoven RF, "Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients" 72 : 1496-1502, 2013

18 Im CH, "Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis" 54 : 808-815, 2015

19 Peters SA, "Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review" 98 : 177-184, 2012

20 Raterman HG, "HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab" 72 : 560-565, 2013

21 Schroeder LL, "Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients" 35 : 1059-1067, 2015

22 Rasch LA, "Glucocorticoid safety for treating rheumatoid arthritis" 14 : 839-844, 2015

23 Benucci M, "Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis" 7 : 69-75, 2013

24 Van Bortel LM, "Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity" 30 : 445-448, 2012

25 Conroy RM, "Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project" 24 : 987-1003, 2003

26 Kerekes G, "Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity" 35 : 398-406, 2008

27 Kerekes G, "Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis" 28 : 705-710, 2009

28 Tomasson G, "Effect of rheumatoid factor on mortality and coronary heart disease" 69 : 1649-1654, 2010

29 Ajeganova S, "Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study" 29 : 942-950, 2011

30 Solomon DH, "Disease activity in rheumatoid arthritis and the risk of cardiovascular events" 67 : 1449-1455, 2015

31 van Gestel AM, "Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria" 39 : 34-40, 1996

32 Hsue PY, "Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis" 3 : e001267-, 2014

33 Novikova DS, "Changes in heart rate, heart rate variability and QT interval in women with rheumatoid arthritis during rituximab treatment" 52 : 270-276, 2014

34 Avouac J, "Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs" 9 : 1121-1128, 2008

35 Mason JC, "Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions" 36 : 482c-489c, 2015

36 Gasparyan AY, "Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research" 18 : 1543-1555, 2012

37 Smolen JS, "A simplified disease activity index for rheumatoid arthritis for use in clinical practice" 42 : 244-257, 2003